Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;94(7):803-811.
doi: 10.1002/ajh.25484. Epub 2019 May 1.

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia

Bruno C Medeiros  1 , Steven M Chan  2 , Naval G Daver  3 , Brian A Jonas  4 , Daniel A Pollyea  5
Affiliations
Review

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia

Bruno C Medeiros et al. Am J Hematol. 2019 Jul.

Abstract

Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML). Monitoring patients for measurable residual disease (MRD) is helpful to identify those at risk for relapse. Hypomethylating agents are being investigated as post-remission therapy. Identification of recurrent genetic alterations that drive disease progression has enabled the design of new, personalized approaches to therapy for patients with AML. Emerging data suggest that targeted post-remission therapy, alone or in combination with chemotherapy, may improve outcomes. Results of ongoing clinical trials will further define potential clinical benefits.

PubMed Disclaimer

Conflict of interest statement

Bruno C. Medeiros ‐ research funds from Astellas, Celgene Corporation, Jazz, and Novartis. Honoraria from Astellas, Celgene Corporation, Jazz, and Novartis.

Steven M. Chan ‐ research funds from Gilead, Celgene Corporation, AbbVie, and Karyopharm. Honorarium from Novartis.

Naval G. Daver: research funds from BMS, Pfizer, Incyte, Servier, AbbVie, Genentech, Immunogen, Nohla Therapeutics, GlycoMimetics, Daiichi‐Sankyo, and Kiromic. Honorarium from Jazz, Pfizer, Otsuka, Celgene Corporation, AbbVie, BMS, Incyte, Immunogen, Agios, Daiichi‐Sankyo, and Novartis.

Brian A. Jonas ‐ research funds to institution from Pharmacyclics, GlycoMimetics, AbbVie, Incyte, Genentech/Roche, Celgene Corporation, Daiichi Sankyo, AROG, Esanex, Forma, Accelerated Medical Diagnostics, and LP Therapeutics. Consultant/Advisory Board for AbbVie, Amgen, Jazz, and Tolero.

Daniel A. Pollyea: research funding from Pfizer, Agios, and AbbVie. Advisory board member for Celgene Corporation, Pfizer, Argenx, Agios, AbbVie, and Celyad.

Figures

Figure 1
Figure 1
Life‐table analysis of duration of remission following induction, then consolidation, with (dark line; n = 71) and without (hatched line; n = 74) long‐term monthly maintenance in patients with AML. Reprinted with permission from Buchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol. 1985;3(12):1583‐158915
See this image and copyright information in PMC

References

    1. National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia. v 1. 2019. National Comprehensive Cancer Network https:// www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed February 5, 2019.
    1. Rollig C, Bornhauser M, Thiede C, et al. Long‐term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29:2758‐2765. - PubMed
    1. Kantarjian H. Acute myeloid leukemia–major progress over four decades and glimpses into the future. Am J Hematol. 2016;91:131‐145. - PubMed
    1. Vasu S, Kohlschmidt J, Mrozek K, et al. Ten‐year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission. Blood Adv. 2018;2:1645‐1650. - PMC - PubMed
    1. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424‐447. - PMC - PubMed

Publication types